Other Events · Jun 8, 2026

Nurix Therapeutics, Inc. entered into a License and Collaboration Agreement with F. Hoffmann-La Roche Ltd. and…

NRIXNurix Therapeutics, Inc.

Nurix Therapeutics, Inc. entered into a License and Collaboration Agreement with F. Hoffmann-La Roche Ltd. and Genentech, Inc. to develop, manufacture, and commercialize bexobrutideg (NX-5948). Roche will provide an upfront cash payment of $700.0 million, and Nurix is eligible for up to $2.3 billion in total potential payments including milestones and royalties.